FDA Alert Targets Dallas-based NuVision Pharmacy

The U.S. Food and Drug Administration (FDA) has issued an alert to healthcare providers not to use sterile products made and distributed by Dallas-based compounding pharmacy NuVision Pharmacy because of concerns about a lack of sterility.

The FDA issued the alert after a recent inspection of the NuVision Dallas facility, where FDA investigators observed what they considered poor sterile production practices.

In April, NuVision recalled methylcobalamin and lyophilized injection products due to a lack of sterility assurance and concerns associated with the quality control processes identified a previous FDA inspection.

Posted in Dallas, News, Pharmaceuticals.